VB-NeoBio Show: New Pharma Investment Roadshow (Guangzhou Station) Successfully Concludes

The VB-NeoBio Show New Medicine Investment and Financing Roadshow was held on March 17 at the Guangzhou Sunshine Hotel. Organized by VCBeat and Qiantu Hui, and co-organized by VB100, Eggshell Research Institute (VCBeat), Arterial Network New Medicine, Fuhui Venture Capital, and Xifan Capital, the event focused on innovative enterprises in areas such as novel drugs and improved drugs. It aimed to build a face-to-face communication platform with industrial capital, striving to present more innovative projects and more diverse, authentic industry perspectives, grasp new trends in industry research and investment, and embrace the power of industrial innovation.

This roadshow invited seasoned investors from Yifeng Capital, Fuhui Venture Capital, Aoyin Capital, Danlu Capital, Qinzi Capital, Shanlan Capital, BOC Guangdong Finance, and GF Qianhe to serve as guest panelists for commentary and interaction.

Participating companies in this roadshow included Hengdong Biologics, Baiyi Biologics, Kangde Biologics, Xinling Pharmaceuticals, iSmile, Fukangren Biologics, and PMI China. They respectively presented their team backgrounds, research achievements, and financing plans within the specific segments of their respective projects. Investor guests engaged in insightful Q&A sessions with the companies, focusing on key highlights of the projects. Questions included: “From a commercialization perspective, among the current clinical candidates for agonistic antibodies, will one or two emerge as successful products?”; “How is treatment efficacy for migraine defined in clinical practice?”; and “What accounts for the discrepancy in placebo response rates resulting from the inconsistent target response rates between LAG macromolecules and LAG small molecules?”

During the capital roundtable discussion, investors deliberated on the following questions: “What are investors’ perceptions of China’s domestic capital market and the current investment and financing landscape?” “Will primary market capital provide better support for the innovative drug sector in the future?” “What is the underlying logic guiding investors’ investment strategies, staging decisions, and benchmarking assessments?” Throughout the dialogue, it became evident that overall investment sentiment in the biopharmaceutical industry remains relatively positive and has not cooled down, with institutions continuing to strategically position themselves in the biopharmaceutical sector. There is a mutual interaction between capital cycles and industrial development; capital growth drives industrial iteration, while companies undergo natural selection—survival of the fittest—during this process. Some investors stated, “The selection of innovative biopharmaceutical projects is not limited merely to therapeutic area or clinical perspectives; greater attention is paid to factors such as the duration of patent protection, technological advantages, and team composition.”

The event concluded with Qiantuhui Pharma sharing over twenty medical device projects.

This roadshow helps innovative projects find suitable institutions and assists investors in discovering higher-quality opportunities. As an acceleration service platform for innovative industries in the life and health sector, VCBeat is committed to helping industry changemakers achieve rapid growth.